Previous Close | 57.65 |
Open | 57.36 |
Bid | 56.55 x 800 |
Ask | 56.68 x 800 |
Day's Range | 56.00 - 58.57 |
52 Week Range | 47.34 - 112.00 |
Volume | |
Avg. Volume | 368,768 |
Market Cap | 1.726B |
Beta (5Y Monthly) | 1.57 |
PE Ratio (TTM) | 3.79 |
EPS (TTM) | 15.03 |
Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 91.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for FLGT
Helio Genomics ("Helio"), and its commercial partner, Fulgent Genetics (NASDAQ: FLGT) ("Fulgent") announced that the American Medical Association (AMA) has issued a new Category I Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses code for HelioLiver™, enabling a reimbursement pathway for potential increased access and broader adoption of innovative surveillance tests for liver cancer in the U.S. The code will become effective on October 1, 2022.
Fulgent Genetics, Inc. (FLGT) closed the most recent trading day at $54.65, moving -0.35% from the previous trading session.
Fulgent Genetics, Inc. (FLGT) closed the most recent trading day at $49.73, moving -0.4% from the previous trading session.